Zevra Therapeutics (ZVRA) Short term Debt (2014 - 2023)

Zevra Therapeutics' (ZVRA) quarterly Short term Debt came in at $37.7 million in Q4 2023, up 5419.77% on a QoQ basis from $683000.0 in Q1 2021.

Zevra Therapeutics (ZVRA) Short term Debt (2014 - 2023) Analysis & Trends

Zevra Therapeutics (ZVRA) has 5 years of Short term Debt data on file, last reported at $37.7 million in Q4 2023.

Quarterly Short term Debt changed N/A year-over-year to $37.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $37.7 million (changed N/A YoY) and the FY2023 annual result came in at $37.7 million, changed N/A from the prior year.
Short term Debt improved to $37.7 million in Q4 2023, from $683000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $37.7 million in Q4 2023 to a low of $390000.0 in Q4 2020.
A 3-year average of $12.9 million and a median of $683000.0 in 2021 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Zevra Therapeutics	671.75 Mn	450.18 Mn	38.18 Mn

Download Data